おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
NorthSea Therapeutics
company
About
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $80M
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Nov 17, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$80M
NorthSea Therapeutics has raised a total of
$80M
in funding over 2 rounds. Their latest funding was raised on
Dec 17, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 17, 2021 | Series C | $80M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
NorthSea Therapeutics is funded by 1 investors.
Hercules Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Hercules Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
